CVS · CVS HEALTH Corp · Financials

$94.75 +2.07 (+2.23%)

S&P 500 member Russell 1000 member Rebalance outlook locked

Market Cap

$118.53B

1.28B

Volume · Oct 20 7.06M Avg daily vol (3M) 8.08M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →

Revenue

$402.07B +7.8%

FY2025

Net Income

$1.77B -61.7%

FY2025

Gross Margin

15.45% -0.8pp

FY2017

Operating Margin

1.16% -1.1pp

FY2025

Diluted EPS

$1.39 -62%

FY2025

Operating Cash Flow

$10.64B +16.8%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2026 (G)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008	FY2007
Revenue	+7.6%	+8.4%	+10.1%	at least $414B	$415.09B	$402.07B^G	$372.81B	$357.78B	$322.47B^G	$292.11B^G	$268.71B	$256.78B	$194.58B	$184.79B	$177.55B	$153.29B	$139.37B	$126.76B	$123.12B	$107.08B	$95.78B	$98.22B	$87.47B	$76.33B
Net Interest Income	—	—	—	—	—	—	—	—	—	—	$0	$0	-$536M	$0	-$1.06B	-$838M	-$600M	-$509M	-$557M	-$584M	-$536M	-$525M	-$509M	-$435M
Premiums Earned (Net)	+16.5%	+14.2%	—	—	$136.64B	$134.75B	$122.9B	$99.19B	$85.33B	$76.13B	$69.36B	$63.12B	$8.18B	$3.56B	—	—	—	—	—	—	—	—	—	—
Cost of Revenue	+4.0%	+6.2%	+5.7%	—	$230.41B	$221.17B	$206.29B	$217.1B	$196.89B	$175.8B	$163.98B	$158.72B	$156.45B	$156.22B	$148.67B	$126.76B	$114B	$102.98B	$100.63B	$86.52B	$75.56B	$77.86B	$69.18B	$60.22B
Gross Profit	+4.0%	+4.9%	+5.9%	—	$29.29B	—	—	—	—	—	—	—	—	$28.55B	$28.86B	$26.53B	$25.37B	$23.78B	$22.49B	$20.56B	$20.22B	$20.36B	$18.29B	$16.11B
Gross Margin	—	—	—	—	—	—	—	—	—	—	—	—	—	15.45%	16.25%	17.31%	18.2%	18.76%	18.27%	19.2%	21.11%	20.73%	20.91%	21.1%
Amortization of Intangibles	+3.4%	-3.3%	+12.5%	—	$1.86B	$1.98B	$2.03B	$1.91B	$1.79B	$2.23B	$2.34B	$2.44B	$1.01B	$817M	$795M	$611M	$518M	$494M	$486M	$452M	—	—	—	—
Depreciation & Amortization	+2.9%	+0.7%	+8.2%	—	$4.52B	$4.61B	$4.6B	$4.37B	$4.22B	$4.49B	$4.44B	$4.37B	$2.72B	$2.48B	$2.48B	$2.09B	$1.93B	$1.87B	$1.75B	$1.57B	$1.47B	$1.39B	$1.27B	$1.1B
Restructuring Charges	—	—	—	—	—	—	—	—	—	—	—	—	—	$215M	—	—	—	—	—	—	—	—	—	—
Total Operating Expenses	+22.1%	+15.1%	+9.2%	—	—	—	—	—	—	—	—	$33.54B	$21.37B	$18.81B	$18.45B	$17.05B	$16.57B	$15.75B	$15.28B	$14.23B	$14.08B	$13.93B	$12.24B	$11.31B
Total Costs & Expenses	+8.1%	+9.3%	—	—	$406.8B	$397.41B	$364.29B	$344.03B	$314.51B	$278.8B	$254.8B	$244.79B	$190.56B	$175.25B	$167.16B	—	—	—	—	—	—	—	—	—
Operating Income	-16.3%	-19.6%	-6.9%	—	$8.29B	$4.66B	$8.52B	$13.74B	$7.95B	$13.31B	$13.91B	$11.99B	$4.02B	$9.54B	$10.39B	$9.48B	$8.8B	$8.04B	$7.21B	$6.33B	$6.14B	$6.43B	$6.05B	$4.79B
Operating Margin	—	—	—	—	—	1.16%	2.28%	3.84%	2.47%	4.56%	5.18%	4.67%	2.07%	5.16%	5.85%	6.18%	6.31%	6.34%	5.86%	5.91%	6.41%	6.54%	6.91%	6.28%
EBITDA	-8.7%	-12.8%	-2.2%	—	$12.81B	$9.27B	$13.11B	$18.11B	$12.18B	$17.8B	$18.35B	$16.36B	$6.74B	$12.02B	$12.86B	$11.57B	$10.73B	$9.91B	$8.96B	$7.9B	$7.61B	$7.81B	$7.32B	$5.89B
Interest Expense	+10.9%	+1.4%	+13.8%	—	$3.1B	$3.12B	$2.96B	$2.66B	$2.29B	$2.5B	$2.91B	$3.04B	$2.62B	$1.06B	$1.08B	$859M	$615M	$517M	$561M	$588M	$539M	$530M	$530M	—
Interest Income	+11.9%	+39.3%	—	—	—	—	—	—	—	—	—	—	—	$21M	$20M	$21M	$15M	$8M	$4M	$4M	$3M	$5M	$21M	—
Other Non-Operating Income	-12.8%	-11.5%	—	—	$118M	$112M	$99M	$88M	$169M	$182M	$206M	$124M	$4M	-$208M	-$28M	—	—	—	—	—	—	—	—	—
Pretax Income	-28.5%	-26.2%	-13.0%	—	$5.79B	$2.14B	$6.15B	$11.17B	$5.84B	$10.54B	$9.77B	$9B	$1.41B	$8.27B	$8.64B	$8.62B	$7.68B	$7.53B	$6.31B	$5.75B	$5.6B	$5.9B	$5.54B	$4.36B
Income Tax	-35.3%	-30.8%	-19.1%	—	$902M	$408M	$1.56B	$2.81B	$1.51B	$2.55B	$2.57B	$2.37B	$2B	$1.64B	$3.32B	$3.39B	$3.03B	$2.93B	$2.44B	$2.26B	$2.18B	$2.2B	$2.19B	$1.72B
Net Income	-25.7%	-24.4%	-10.3%	—	$4.89B	$1.77B	$4.61B	$8.34B	$4.31B	$8B	$7.18B	$6.63B	-$594M	$6.62B	$5.32B	$5.24B	$4.64B	$4.59B	$3.86B	$3.46B	$3.43B	$3.7B	$3.2B	$2.64B
Net Margin	—	—	—	—	—	0.44%	1.24%	2.33%	1.34%	2.74%	2.67%	2.58%	-0.31%	3.58%	2.99%	3.42%	3.33%	3.62%	3.14%	3.23%	3.58%	3.76%	3.66%	3.45%
Net Income Attributable to Noncontrolling Interests	—	—	—	—	-$5M	-$40M	-$28M	$24M	$16M	-$12M	$13M	-$3M	-$2M	$1M	$2M	$2M	$0	$0	-$2M	-$4M	-$3M	—	—	—
Net Income Available to Common Stockholders	-25.7%	—	-10.3%	—	$4.89B	$1.77B	$4.61B	$8.34B	$4.31B	$8B	—	—	—	—	—	$5.24B	$4.64B	$4.59B	$3.86B	$3.46B	$3.43B	$3.7B	$3.2B	$2.62B
Comprehensive Income	-5.4%	-21.2%	-7.7%	—	$4.81B	$2.29B	$4.79B	$9.31B	$2.71B	$7.69B	$7.57B	$7.55B	-$320M	$6.76B	$5.37B	$5.1B	$4.58B	$4.62B	$3.86B	$3.43B	$3.42B	—	—	—
EPS (Basic) USD/shares	-24.8%	-23.9%	-11.3%	—	$3.82	$1.40	$3.67	$6.49	$3.29	$6.07	$5.48	$5.10	-$0.57	$6.47	$4.93	$4.66	$3.98	$3.77	$3.04	$2.59	$2.51	$2.58	$2.23	$1.97
EPS (Diluted) USD/shares	-24.7%	-23.9%	-11.3%	$6.84 – $7.04	$3.79	$1.39^G	$3.66^G	$6.47^G	$3.26^G	$6.02^G	$5.46	$5.08	-$0.57	$6.44	$4.90	$4.63	$3.96	$3.74	$3.02	$2.57	$2.49	$2.55	$2.18	$1.92
Shares Outstanding (Basic Avg) shares	-1.2%	-0.7%	+1.3%	—	—	1.27B	1.26B	1.29B	1.31B	1.32B	1.31B	1.3B	1.04B	1.02B	1.07B	1.12B	1.16B	1.22B	1.27B	1.34B	1.37B	1.43B	1.43B	1.33B
Shares Outstanding (Diluted Avg) shares	-1.3%	-0.7%	+1.2%	—	—	1.27B	1.26B	1.29B	1.32B	1.33B	1.31B	1.31B	1.04B	1.02B	1.08B	1.13B	1.17B	1.23B	1.28B	1.35B	1.38B	1.45B	1.47B	1.37B

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $47.04B in buybacks, $33.68B in dividends.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balance	As of	Amount	Source
Current long-term debt and lease obligations	2026-06-30	USD 1,958,000,000	10-Q filed 2026-08-05
Current operating lease liabilities	2026-06-30	USD 1,914,000,000	10-Q filed 2026-08-05
Noncurrent long-term debt and lease obligations	2026-06-30	USD 59,452,000,000	10-Q filed 2026-08-05
Noncurrent operating lease liabilities	2026-06-30	USD 12,982,000,000	10-Q filed 2026-08-05

Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

0.42×

Peer median 0.37×

EV/EBIT

20.81×

Peer median 17.00×

P/E (TTM)

24.45×

Peer median 19.05×

Peer medians compare against the 5 similar-size Healthcare Plans companies (of 13 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Health Services Segment	$190,425,000,000	$173,605,000,000	$186,843,000,000	$169,576,000,000	$153,892,000,000	—	—	—
Health Care Benefits Segment	$143,354,000,000	$130,665,000,000	$105,646,000,000	$91,350,000,000	$82,119,000,000	$75,467,000,000	$69,604,000,000	$8,962,000,000
Pharmacy and Consumer Health Segment	$139,367,000,000	$124,500,000,000	$116,763,000,000	$108,596,000,000	$101,620,000,000	—	—	—
Pharmacy Services Segment	—	—	—	$169,236,000,000	$153,022,000,000	$141,938,000,000	$141,491,000,000	$134,736,000,000
Retail Long-Term Care Segment	—	—	—	$106,594,000,000	$100,105,000,000	$91,198,000,000	$86,608,000,000	$83,989,000,000
Corporate And Other	—	—	—	—	—	—	$512,000,000	$606,000,000

By Product & Service (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Product	$249,908,000,000	$231,521,000,000	$245,138,000,000	$226,616,000,000	$203,738,000,000	$190,688,000,000	$185,236,000,000	$183,910,000,000
Service	$15,175,000,000	$16,239,000,000	$12,293,000,000	$9,683,000,000	$11,042,000,000	$7,856,000,000	$7,407,000,000	$1,825,000,000
Front Store Revenue	—	—	—	—	—	—	$19,422,000,000	$19,055,000,000
Pharmacy Revenue	—	—	—	—	—	—	$165,899,000,000	$164,845,000,000
Premiums	—	—	—	—	—	—	$63,122,000,000	$8,184,000,000
Product And Service Other	—	—	—	—	—	—	$7,322,000,000	$1,835,000,000

Key facts CIK 64803 CUSIP 126650100 13F (30d) 405 filings 354 filers Visit website Investor relations